Telix Pharmaceuticals Limited (TLX)

Market Cap	5.81B
Revenue (ttm)	484.69M
Net Income (ttm)	30.89M
Shares Out	329.55M
EPS (ttm)	0.09
PE Ratio	190.53
Forward PE	73.77
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,844
Open	17.41
Previous Close	17.75
Day's Range	16.85 - 17.60
52-Week Range	13.61 - 30.36
Beta	2.38
Analysts	Strong Buy
Price Target	22.00 (+29.03%)
Earnings Date	n/a

About TLX

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 415
• Stock Exchange: NASDAQ
• Ticker Symbol: TLX
• Website: https://telixpharma.com

Financial Performance

In 2024, Telix Pharmaceuticals's revenue was 783.21 million, an increase of 55.85% compared to the previous year's 502.55 million. Earnings were 49.92 million, an increase of 857.95%.

Financial numbers in AUD

Analyst Forecast

According to one analyst, the rating for TLX stock is "Strong Buy" and the 12-month stock price forecast is $22.0.

Price Target

$22.0

(29.03% upside)

Analyst Consensus: Strong Buy